Faculty

Ashraf Z. Badros, M.B, ChB
Professor, Department of Medicine, University of Maryland School of Medicine, Stem Cell Transplant Program M & S, Greenebaum Cancer Center
Baltimore, MD

Myron Czuczman, MD
Head, Lymphoma/Myeloma Service, Roswell Park Cancer Institute, Associate Professor of Medicine, School of Medicine, State University of New York Buffalo, NY

Richard Gralla, MD
Professor of Medical Oncology, North Shore Long Island Jewish Medical Center, Medical Oncology Monter Cancer Center
Lake Success, NY

Sergio Giralt, MD
Chief of the Adult Bone Marrow Transplantation Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center
New York, NY

Fredrick B. Hagemeister, MD
Professor of Hematology/Oncology, Department of Medicine, The University of Texas MD Anderson Cancer Center
Houston, TX

Steve Horwitz, MD
Assistant Attending, Medical Oncologist, Lymphoma, Cutaneous Lymphomas, T-cell lymphoma, Memorial Sloan-Kettering Cancer Center
New York, NY

Jonatham L. Kaufman, MD
Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Atlanta, GA

Bonnie Kirschenbaum, MS
Healthcare Consultant and Columnist
Breckenridge, CO

Shaji Kumar, MD
Associate Professor of Medicine, Division of Hematology, Mayo Clinic
Rochester, MN

Heather Landau, MD
Adult Bone Marrow Transplantation Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center
New York, NY

John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Professor of Medicine, Associate Director for Clinical Research, Weill Cornell Cancer Center, Weill Cornell Medical College, Attending Physician, New York Presbyterian Hospital
New York, NY

Ruben Mesa, MD
Consultant Hematologist, Chair, Division of Hematology and Medical Oncology, Professor of Medicine, Mayo Clinic
Scottsdale, AZ

Joseph Mikhail, MD
Consultant Hematologist, Mayo Clinic Arizona; Assistant Professor, Mayo College of Medicine
Scottsdale, AZ

Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia

Saturday, May 12, 2012

Omni Mandalay Hotel at Las Colinas
221 East Las Colinas Boulevard, Irving, TX 75039 • Phone: (972) 556-0800

Statement of Need/Program Overview

This symposium is intended to improve care of patients with hematological malignancies by accelerating adoption of new guidelines and evidence-based practice change. In addition to chemotherapy and targeted therapy of hematological malignancies, this symposium will focus on individualized therapy based on emerging agents currently in development, supportive care therapy and cost and reimbursement issues. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty. In-depth discussion of novel agents at various stages of clinical development will be given significant focus.

Target Audience

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new developments for treatment of hematological malignancies. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Learning Objectives

After completing this activity, the participant should be better able to:

• Review the role of risk stratification and upfront therapies in multiple myeloma
• Examine novel approaches in the treatment of relapsed multiple myeloma
• Update the strategies and controversies of maintenance therapy for multiple myeloma
• Describe novel therapies in the management of Hodgkin lymphoma
• Explain the management options for aggressive lymphomas
• Update in the treatment and management options for indolent lymphomas
• Cite the novel treatment options in the management of T-cell lymphomas
• Evaluate the risk stratified therapy of chronic lymphocytic leukemia (CLL)
• Identify updates in the management of chronic myelogenous leukemia (CML)
• Examine the treatment options in the management of myelodysplastic syndrome (MDS)
• Discuss practice guidelines and its impact on cost and reimbursement issues in the management of hematological malignances
• Cite the importance of supportive care in the management of hematological malignances
Agenda

Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia, Irving, TX - May 12, 2012

7:00 AM Breakfast and Registrations
7:55 AM Welcome and Introductions

MULTIPLE MYELOMA

8:00 AM Updates in the Management of Transplantation-Eligible Patients With Newly Diagnosed Myeloma
Heather Landau, MD

8:25 AM Optimal Use of Stem Cell Transplantation in the Management of Multiple Myeloma
Jonathan L. Kaufman, MD

8:50 AM Case Report and Panel Discussion
Heather Landau, MD / Jonathan Kaufman, MD

9:05 AM Maintenance Therapy in the Management of Multiple Myeloma
Ashraf Z. Badros, MD

9:30 AM Recent Approaches in the Treatment of Relapsed and Refractory Multiple Myeloma
Joseph Mikhael, MD

9:55 AM New Drugs and Clinical Trials in Management of Multiple Myeloma
Shaji Kumar, MD

10:20 AM Case Report and Panel Discussion
Ashraf Z. Badros, MD / Joseph Mikhael, MD / Shaji Kumar, MD

10:35 AM BREAK

LYMPHOMA

10:45 AM Overview of Treatment Options and Role of Novel Therapies in the Management of Hodgkin Lymphoma
Fredrick Hagemeister, MD

11:00 AM Overview of Treatment Options and Role of Novel Therapies in the Management of Aggressive Lymphomas
John P. Leonard, MD

11:15 AM Overview of Treatment Options and Role of Novel Therapies in the Management of Indolent Lymphomas
Myron Czuczman, MD

12:00 PM Overview of Treatment Options in the Management of Cutaneous T-Cell Lymphomas
Steve Horwitz, MD

12:25 PM Case Report and Panel Discussion
Fredrick Hagemeister, MD / John Leonard, MD / Myron Czuczman, MD / Steve Horowitz, MD

12:40 PM LUNCH

LEUKEMIA

1:40 PM Overview of Risk Stratified Therapy of Chronic Lymphocytic Leukemia (CLL)
TBD

2:05 PM Overview and Update in the Management of Chronic Myelogenous Leukemia (CML)
Sergio Giralt, MD

2:30 PM Overview of New Approaches in the Treatment Options for Myelodysplastic Syndromes (MDS)
Ruben Mesa, MD

2:55 PM Case Report and Panel Discussion
TBD / Sergio Giralt, MD / Ruben Mesa, MD

Cost and Reimbursement Issues and Supportive Care

3:10 PM Supportive Care Issues in the Management of Hematological Malignancies
Richard Gralla, MD

3:35 PM Cost and Reimbursement Issues in the Management of Hematological Malignancies
Bonnie Kirschenbaum, MD

4:00 PM Closing Remarks and Adjourn
Fredrick Hagemeister, MD/ Joseph Mikhael, MD

Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Accreditation Statement
American Health Resources, Inc. is approved as a licensed continuing education provider (CPE #14254) in the State of California. Programs approved by CA BRN are accepted by most State Boards of Nursing.

Credit Designation
This educational activity is approved for 7.0 contact hours.

Pharmacist Continuing Education
Accreditation Statement
American Health Resource is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This activity provides 7.0 contact hour (0.70 CEU) of continuing education credit.

The ACPE Universal Activity Number is: 0280-9999-12-034-L01-P Knowledge based
Initial Release Date: May 12, 2012

To receive credit participants must fully attend this session as well as pass in a completed signature verification sheet and session evaluation form. A statement of credit will be mailed within six weeks.

All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.

Participants may reserve guest rooms at a reduced block rate by calling (972) 356-0800

860 Hebron Pkwy, Suite 1104
Lewisville, TX 75057